Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient...

Area of Science:

• Oncology
• Immunotherapy
• Biomarker Discovery

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer (NSCLC) treatment, but patient response varies significantly.
• Many NSCLC patients do not benefit from ICIs, experiencing hyper-progressive disease or immune-related adverse events.
• Current biomarkers like PD-L1 and tumor mutational burden (TMB) have limitations for predicting ICI efficacy.

Purpose of the Study:

• To review the development and potential of novel plasma biomarkers for predicting response and toxicity in NSCLC patients undergoing ICI therapy.
• To highlight the limitations of existing biomarkers and the promise of blood-based markers.
• To discuss emerging plasma biomarkers including soluble proteins, ctDNA, blood TMB, and blood microbiome.

Main Methods:

• Literature review of studies on plasma biomarkers in NSCLC patients treated with ICIs.
• Analysis of the development and validation of novel plasma biomarkers.
• Discussion of the predictive and prognostic value of these biomarkers.

Main Results:

• Existing biomarkers (PD-L1, TMB) have limitations in predicting ICI response in NSCLC.
• Plasma biomarkers, including soluble proteins, ctDNA, blood TMB, and blood microbiome, are emerging as promising tools.
• These novel biomarkers may offer improved prediction of response and toxicity for ICI therapy in NSCLC.

Conclusions:

• There is a critical need for robust biomarkers to guide ICI treatment selection in NSCLC.
• Plasma-derived biomarkers represent a promising, less invasive approach for predicting ICI efficacy and toxicity.
• Further research and validation are essential to integrate these novel plasma biomarkers into clinical practice for NSCLC management.